Leo Mavely

3 days ago 12

Shellfish exoskeletons don’t usually have a place on the battlefield. But to Axio Bio­solutions, led by bioengineer Leo Mavely, they are essential ingredients for fast-acting wound care. From his own experience about two decades ago in Delhi, when he stepped in to help a hemorrhaging accident survivor, came the Axiostat bandage: the first Indian hemostatic product to receive 510(k) clearance from the U.S. Food and Drug Administration in 2018. Axiostat uses chitosan, derived from chitin in shrimp shells, to swiftly stop bleeding. Mavely says Axio’s product has been used across multiple scenarios, from road accidents to medical procedures, in more than 50 countries—including war-torn Ukraine. Another of Mavely’s hemostatic products, MaxioCel, used for longer-­term wound management, also got nationwide distribution in the U.S. this year. “Innovation in healthcare doesn’t always come from discovering something new,” Mavely wrote in May. “Sometimes, it comes from re-seeing what we already have.”

*** Disclaimer: This Article is auto-aggregated by a Rss Api Program and has not been created or edited by Bdtype.

(Note: This is an unedited and auto-generated story from Syndicated News Rss Api. News.bdtype.com Staff may not have modified or edited the content body.

Please visit the Source Website that deserves the credit and responsibility for creating this content.)

Watch Live | Source Article